BioStock: Saniona´s CMO on the FDA’s Orphan Drug Designation for Tesomet in Prader-Willi Syndrome

Saniona yesterday announced that the FDA has granted Orphan Drug Designation (ODD) for the drug candidate Tesomet in the treatment of Prader-Willi syndrome (PWS). BioStock reached out to Rudolf Baumgartner, M.D., Chief Medical Officer and Head of Clinical Development at Saniona, to get his view on this important milestone and in what ways the ODD will help Saniona going forward.

Read the full interview with Rudolf Baumgartner at biostock.se:

https://www.biostock.se/en/sanionas-cmo-on-the-fdas-orphan-drug-designation-for-tesomet-in-prader-willi-syndrome/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se